Gambia
Tuberculosis profile
Population  2013 1.8 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.37 (0.16–0.61) 20 (8.6–33)
Mortality (HIV+TB only) 0.11 (0.069–0.15) 5.8 (3.7–8.3)
Prevalence  (includes HIV+TB) 2.3 (1.8–3) 127 (96–162)
Incidence  (includes HIV+TB) 3.2 (2.7–3.8) 173 (146–204)
Incidence (HIV+TB only) 0.47 (0.39–0.57) 26 (21–31)
Case detection, all forms (%) 73 (62–86)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.5 (0–2.6) 0 (0–18)
MDR-TB cases among notified pulmonary
TB cases
10 (0–54) 0 (0–23)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 431   70
Pulmonary, clinically diagnosed 653   0
Extrapulmonary 171   0
       
Total new and relapse 2 325    
Previously treated, excluding relapses 56    
Total cases notified 2 381    
Among 2 325 new and relapse cases:
137 (6%) cases aged under 15 years; male:female ratio: 1.9
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 90 (71%) 90
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 850 (78)
HIV-positive TB patients 258 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 238 (92)
HIV-positive TB patients on antiretroviral therapy (ART) 101 (39)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 85
Previously treated cases, excluding relapse, registered in 2012 77
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.8
Culture (per 5 million population) 2.7
Drug susceptibility testing (per 5 million population) 2.7
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-22 Data: www.who.int/tb/data